Reducing the effective dose of cisplatin using gold nanoparticles as carriers

González-López, Marco A.; Gutiérrez-Cárdenas, Elena Marcia; Sánchez-Cruz, C.; Hernández-Paz, J.F.; Perez, Irma Ruth; Olivares-Trejo, José J.; Hernández-González, Olivia

doi:10.1186/s12645-020-00060-w

Cited by 23 publications

(15 citation statements)

References 44 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Prospects Of Using Gnps With Other Radiosensitizersmentioning

confidence: 99%

“…Furthermore, GNPs could be used as a cisplatin delivery vehicle [ 72 ]. A recent study showed that if GNPs are used as drug carriers, the amount of cisplatin necessary to cause the desired cytotoxic effect would be less than the amount used in conventional cancer treatments [ 72 ]. For example, IC 50 diminished approximately 7 times, compared to the IC 50 of cisplatin used alone, when using GNPs as delivery vehicles (see Figure 6 ) [ 72 ].…”

Section: Prospects Of Using Gnps With Other Radiosensitizersmentioning

confidence: 99%

“…Cell viability curve of ( a ) HeLa cells, ( b ) C6 cells, and ( c ) AGS cells. Reproduced with permission from [ 72 ], American Chemical Society, 2007.…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Combining Gold Nanoparticles with Other Radiosensitizing Agents for Unlocking the Full Potential of Cancer Radiotherapy

2021

View full text Add to dashboard Cite

About half of cancer patients (50%) receive radiotherapy (RT) for the treatment of local tumors. However, one of the main obstacles in RT is the close proximity of adjacent organs at risk, resulting in treatment doses being limited by significant tissue toxicity, hence preventing the necessary dose escalation that would guarantee local control. Effective local cancer therapy is needed to avoid progression of tumors and to decrease the development of systemic metastases which may further increase the possibility of resection. In an effort to do so, radiosensitizing agents are introduced to further increase damage to the tumor while minimizing normal tissue toxicity. Cisplatin and docetaxel (DTX) are currently being used as radiation dose enhancers in RT. Recent research shows the potential of gold nanoparticles (GNPs) as a radiosensitizing agent. GNPs are biocompatible and have been tested in phase I clinical trials. The focus will be on exploring the effects of adding other radiosensitizing agents such as DTX and cisplatin to the GNP-RT platform. Therefore, a combined use of local radiosensitizing agents, such as GNPs, with currently available radiosensitizing drugs could make a significant impact in future RT. The ultimate goal is to develop treatments that have limited or nonexistent side effects to improve the quality of life of all cancer patients.

show abstract

Section: Prospects Of Using Gnps With Other Radiosensitizersmentioning

confidence: 99%

Section: Prospects Of Using Gnps With Other Radiosensitizersmentioning

confidence: 99%

See 1 more Smart Citation

Combining Gold Nanoparticles with Other Radiosensitizing Agents for Unlocking the Full Potential of Cancer Radiotherapy

2021

View full text Add to dashboard Cite

show abstract

“…As most studies have mainly focused on tumor cells, our study is designed to elucidate the NP interactions in tumor cells and in CAFs. We used gold nanoparticles (GNPs) as our model NP system, since they can be used as a radiation dose enhancer in radiotherapy and a drug carrier in chemotherapy [15][16][17][18][19]. The biocompatibility of GNPs has been determined in a phase I clinical trial [20].…”

Section: Introductionmentioning

confidence: 99%

Docetaxel-Mediated Uptake and Retention of Gold Nanoparticles in Tumor Cells and in Cancer-Associated Fibroblasts

Alhussan

Bromma

Monica

et al. 2021

Cancers

View full text Add to dashboard Cite

Due to recent advances in nanotechnology, the application of nanoparticles (NPs) in cancer therapy has become a leading area in cancer research. Despite the importance of cancer-associated fibroblasts (CAFs) in creating an optimal niche for tumor cells to grow extensively, most of the work has been focused on tumor cells. Therefore, to effectively use NPs for therapeutic purposes, it is important to elucidate the extent of NP uptake and retention in tumor cells and CAFs. Three tumor cell lines and three CAF cell lines were studied using gold NPs (GNPs) as a model NP system. We found a seven-fold increase in NP uptake in CAFs compared to tumor cells. The retention percentage of NPs was three-fold higher in tumor cells as compared to CAFs. Furthermore, NP uptake and retention were significantly enhanced using a 50 nM concentration of docetaxel (DTX). NP uptake was improved by a factor of three in tumor cells and a factor of two in CAFs, while the retention of NPs was two-fold higher in tumor cells compared to CAFs, 72 h post-treatment with DTX. However, the quantity of NPs in CAFs was still three-fold higher compared to tumor cells. Our quantitative data were supported by qualitative imaging data. We believe that targeting of NPs in the presence of DTX is a very promising approach to accumulate a higher percentage of NPs and maintain a longer retention in both tumor cells and CAFs for achieving the full therapeutic potential of cancer nanotechnology.

show abstract

“…Among other NP systems, we used GNPs as a model NP system for this study due to their promising results in several practiced clinical applications including RT and CT as described in Fig. 1 (left most) (Chithrani et al 2010 ; González-López et al 2020 ; Khoo et al 2017 ; Paciotti et al 2016 ). Biocompatibility of GNPs and their ability to act as a vector for targeted drug delivery to the tumor were demonstrated successfully in a phase I clinical trial (Libutti et al 2010 ).…”

Section: Introductionmentioning

confidence: 99%

Elucidating the fate of nanoparticles among key cell components of the tumor microenvironment for promoting cancer nanotechnology

et al. 2020

View full text Add to dashboard Cite

Successful integration of nanotechnology into the current paradigm of cancer therapy requires proper understanding of the interface between nanoparticles (NPs) and cancer cells, as well as other key components within the tumor microenvironment (TME), such as normal fibroblasts (FBs) and cancer-associated FBs (CAFs). So far, much focus has been on cancer cells, but FBs and CAFs also play a critical role: FBs suppress the tumor growth while CAFs promote it. It is not yet known how NPs interact with FBs and CAFs compared to cancer cells. Hence, our goal was to elucidate the extent of NP uptake, retention, and toxicity in cancer cells, FBs, and CAFs to further understand the fate of NPs in a real tumor-like environment. The outcome of this would guide designing of NP-based delivery systems to fully exploit the TME for a better therapeutic outcome. We used gold nanoparticles as our model NP system due to their numerous applications in cancer therapy, including radiotherapy and chemotherapy. A cervical cancer cell line, HeLa, and a triple-negative breast cancer cell line, MDA-MB-231 were chosen as cancer cell lines. For this study, a clinically feasible 0.2 nM concentration of GNPs was employed. According to our results, the cancer cells and CAFs had over 25-and 10-fold higher NP uptake per unit cell volume compared to FBs, respectively. Further, the cancer cells and CAFs had over 30% higher NP retention compared to FBs. There was no observed significant toxicity due to GNPs in all the cell lines studied. Higher uptake and retention of NPs in cancer cells and CAFs vs FBs is very important in promoting NP-based applications in cancer therapy. Our results show potential in modulating uptake and retention of GNPs among key components of TME, in an effort to develop NP-based strategies to suppress the tumor growth. An ideal NP-based platform would eradicate tumor cells, protect FBs, and deactivate CAFs. Therefore, this study lays a road map to exploit the TME for the advancement of "smart" nanomedicines that would constitute the next generation of cancer therapeutics.

show abstract

Reducing the effective dose of cisplatin using gold nanoparticles as carriers

Cited by 23 publications

References 44 publications

Combining Gold Nanoparticles with Other Radiosensitizing Agents for Unlocking the Full Potential of Cancer Radiotherapy

Combining Gold Nanoparticles with Other Radiosensitizing Agents for Unlocking the Full Potential of Cancer Radiotherapy

Docetaxel-Mediated Uptake and Retention of Gold Nanoparticles in Tumor Cells and in Cancer-Associated Fibroblasts

Elucidating the fate of nanoparticles among key cell components of the tumor microenvironment for promoting cancer nanotechnology

Contact Info

Product

Resources

About